Home › Funds › 22NW, LP › NKTR
22NW, LP position in NKTR
NEKTAR THERAPEUTICS · Health Care
22NW, LP reported holding 281,115 shares of NKTR (NEKTAR THERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$17.0M, representing 11.79% of its reported portfolio and ranking #2 among its reported holdings. 22NW, LP has disclosed NKTR holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How 22NW, LP's NKTR position evolved
22NW, LP first disclosed a stake in NKTR in Q4 2024 at 2,191,750 shares (US$2.0M). The position peaked in Q1 2026 at 281,115 shares, worth US$20.2M. Across 8 filings, 22NW, LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 281,115 shares valued at US$17.0M. Notable position changes include a 93% trim in Q2 2025 (shares rose 120% over the following quarter), a 127% increase in Q3 2025 (shares fell 26% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 2.19M | $2.04M | New |
| Q1 2025 | 2.19M | $1.49M | Hold |
| Q2 2025 | 146.12K | $3.78M | Reduce |
| Q3 2025 | 331.12K | $18.84M | Add |
| Q4 2025 | 331.12K | $14.00M | Hold |
| Q1 2026 | 281.12K | $20.23M | Reduce |
| Q2 2026 | 281.12K | $19.62M | Hold |
| Q3 2026 | 281.12K | $17.02M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NKTR and 13F data
NKTR (NEKTAR THERAPEUTICS) is a Health Care company. 56 other funds we track also report a position in NKTR — the largest reported positions include Two Seas Capital LP (US$202.6M), BVF INC/IL (US$166.9M), Vestal Point Capital, LP (US$69.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NKTR
- Two Seas Capital LP 3.35M sh · $202.58M · Q3 2026
- BVF INC/IL 2.39M sh · $166.92M · Q2 2026
- Vestal Point Capital, LP 1.00M sh · $69.81M · Q2 2026
- ARMISTICE CAPITAL, LLC 724.00K sh · $50.54M · Q2 2026
- Prosight Management, LP 785.00K sh · $47.53M · Q3 2026
- BRAIDWELL LP 473.62K sh · $33.06M · Q2 2026
- Sofinnova Investments, Inc. 471.76K sh · $32.93M · Q2 2026
- ORBIMED ADVISORS LLC 465.35K sh · $32.49M · Q2 2026
- DAFNA Capital Management LLC 318.38K sh · $22.23M · Q2 2026
- ADAR1 Capital Management, LLC 244.18K sh · $17.05M · Q2 2026
- SEVEN GRAND MANAGERS, LLC 240.00K sh · $16.75M · Q2 2026
- Bronte Capital Management Pty Ltd. 202.06K sh · $12.23M · Q3 2026
FAQ
How long has 22NW, LP held NKTR?
22NW, LP has disclosed NKTR holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is 22NW, LP's current position in NKTR?
As of Q3 2026, 22NW, LP holds 281.12K shares of NKTR (NEKTAR THERAPEUTICS), valued at $17.02M, representing 11.79% of its reported portfolio and ranking #2.
Has 22NW, LP been buying or selling NKTR?
In the latest 13F filing (Q3 2026), 22NW, LP held unchanged its position in NKTR. The position peaked in Q1 2026 at 281.12K shares.
Which other funds hold NKTR?
Other major institutional holders of NKTR include Two Seas Capital LP, BVF INC/IL, Vestal Point Capital, LP, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.